SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
___________________
Date of Report (Date of earliest event reported) October 11, 2000
BICO, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania 0-10822 25-1229323
(State of other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
2275 Swallow Hill Road, Bldg. 2500, Pittsburgh, Pennsylvania 15220
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (412) 429-0673
_______________________________________________________
(Former name or former address,
if changes since last report.)
Item 1. Change in Control of Registrant.
Not applicable.
Item 2. Acquisition or Disposition of Assets.
Not applicable.
Item 3. Bankruptcy or Receivership.
Not applicable.
Item 4. Changes in Registrant's Certifying Accountant
Not applicable.
Item 5. Other Events.
Biocontrol Technology, Inc., a division of BICO,
Inc. announced today it plans to begin a
controlled clinical study for its noninvasive
glucose monitor, the Diasensor 2000. The multi-
center trial will begin at the Joslin Diabetes
Center in Boston in approximately ten days, and,
under the direction of Joslin personnel, two
additional centers will be included in the study.
Item 6. Resignation of Registrant's Directors.
Not Applicable
Item 7. Financial Statement, Pro Forma Financial Information and Exhibits.
(a) Financial Statements and Businesses Acquired - Not Applicable.
(b) Pro Forma Financial Information - Not Applicable.
(c) Exhibits - Press Release.
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act of 1934, the
Registrant has duly caused this Report to be signed on its behalf by the
undersigned hereunto duly authorized.
BICO, INC.
by /s/ Fred E. Cooper
Fred E. Cooper, CEO
DATED: October 11, 2000
NEWS RELEASE
BIOCONTROL TECHNOLOGY, INC.
625 Kolter Drive , Indiana, PA 15701
Investors: Media:
Diane McQuaide Nancy Saxman
Phone 412-429-0673 Phone 724-349-1811
Fax 412-279-9690 Fax 724-349-8610
For immediate release
BIOCONTROL TECHNOLOGY TO BEGIN DIASENSOR CLINICAL TRIALS
Pittsburgh, Pa. - October 11, 2000 - Biocontrol
Technology, Inc., a division of BICO, Inc. (OTCBB:BIKO),
announced today it plans to begin a controlled clinical
study for its noninvasive glucose monitor, the Diasensor
2000. The multi-center trial will begin at the Joslin
Diabetes Center in Boston in approximately ten days, and,
under the direction of Joslin personnel, two additional
centers will be included in the study.
The Diasensor 2000 will be evaluated for the treatment
of diabetic patients within a system of care that includes
home use of the Diasensor and regular evaluation of a
patient's blood glucose trends as determined by the device.
The Diasensor contains a telemedicine feature that
automatically transmits the patient's glucose measurements
to a secure website on the Internet where they can be viewed
by the healthcare provider.
Biocontrol Technology, Inc. has research, development
and manufacturing facilities in Indiana, Pa. BICO's
corporate offices are located in Pittsburgh, Pa. BICO is
involved in the development and manufacture of biomedical
devices and environmental products.
#####
WEBSITE: www.bico.com
INVESTOR RELATIONS NEWSLINE NUMBER: 1-800-357-6204
This press release contains statements of a forward-looking
nature. Shareholders and potential investors are cautioned
that such statements are predictions and actual events or
results may vary significantly.
